• Trifluoperazine 2HCl: Evidence and Research Context

  2026-10-09

  Trifluoperazine 2HCl is best viewed as a pharmacological research probe linking dopamine D2 receptor signaling with broader phenothiazine biology. Recent preclinical work supports a host-directed antibacterial concept involving macrophage ROS, lysosomal activity, and autophagy, but it does not establish trifluoperazine-specific efficacy, D2 dependence, or clinical utility.

• Ciclesonide: Mechanism, Evidence, and Research Limits

  2026-10-09

  Ciclesonide is a glucocorticoid receptor agonist prodrug whose active metabolite, desisobutyryl-ciclesonide, shows substantially greater reported potency. Evidence supports its relevance to asthma treatment research and allergic rhinitis treatment, but the supplied ERAD study concerns desonide rather than ciclesonide.

• CSBTA Pharmacokinetics in MASH: Key Findings

  2026-10-08

  A 2025 study integrated plasma pharmacokinetics, tissue distribution, cellular accumulation, transporter assays, and metabolic-enzyme analyses to examine how MASH-like pathology alters the disposition of Corydalis saxicola Bunting total alkaloids. Its findings indicate that disease state and repeated exposure can increase systemic and hepatic exposure to key alkaloids, while also implicating CYP450 enzymes, Oatp1b2, P-glycoprotein, and PXR in the observed variability.

• A-1210477: Reading MCL-1 Dependence

  2026-10-08

  A-1210477 is an MCL-1 inhibitor useful for interpreting how cancer cell survival regulation connects to mitochondrial apoptosis. This evidence-focused guide distinguishes target engagement, cellular response, and translational relevance while placing product-reported activity alongside breast cancer findings.

• DMH1 and ALK2 in Organoid Research

  2026-10-07

  DMH1 is a vendor-described ALK2 inhibitor that provides a pharmacological way to investigate BMP signaling. Its reported Smad1/5/8 phosphorylation inhibition is relevant to organoid and non-small cell lung cancer research, but the supplied intestinal organoid study does not establish DMH-1 as the causal compound.

• miR-18a, ALOXE3, and Glioblastoma Ferroptosis

  2026-10-07

  The reference study identifies a miR-18a/ALOXE3 axis that links lipid metabolism to ferroptosis resistance and migration in glioblastoma. Its integrated cellular, molecular, lipid-mediator, and orthotopic-model evidence supports ALOXE3 as a mechanistic regulator of tumor progression, while also defining important limits for translation beyond the studied models.

• Pep 14 and Senescence in Human Skin Models

  2026-10-06

  The reference study identifies Pep 14 as a senomorphic peptide that reduced senescence burden across several human skin models and was associated with PP2A-related changes in cell-cycle and DNA-repair programs. Its ex vivo skin findings, including lower senescence markers and reduced DNA methylation age, are promising but remain limited to experimental tissue models rather than clinical evidence.

• Nadolol (SQ-11725): Evidence and Research Context

  2026-10-06

  Nadolol (SQ-11725) is a non-selective beta-adrenergic receptor blocker with established pharmacological relevance to cardiovascular research. A 2025 mouse study of Corydalis saxicola alkaloids offers a transporter-aware pharmacokinetic framework, but it is not direct evidence for Nadolol efficacy or disposition.

• THBS1 in Laryngeal Cancer: Evidence and Implications

  2026-10-05

  A 2025 integrative study combined public transcriptomic datasets, machine-learning feature selection, survival analysis, pathway evaluation, and cell-based validation to identify THBS1 as a prognostic biomarker and possible therapeutic vulnerability in laryngeal cancer. Its findings connect THBS1 expression with epithelial-to-mesenchymal transition, integrin signaling, lipid metabolism, and an immune-suppressive tumor microenvironment, while also highlighting the need for prospective clinical validation.

• Sabutoclax: Evidence, Context, and Limitations

  2026-10-04

  Sabutoclax is a reported pan-Bcl-2 inhibitor and apogossypolone derivative investigated as a small-molecule apoptosis inducer in cancer models. Available evidence suggests activity across several anti-apoptotic Bcl-2 family proteins, but interpretation is limited by reliance on supplier-reported data, model-specific responses, and the distinction between reduced viability, growth arrest, and actual cell death.

• Glioblastoma and BH3-Mimetic Apoptotic Targeting

  2026-10-03

  Koessinger and colleagues show that glioblastoma, including patient-derived stem-like cells, has elevated dependence on the anti-apoptotic proteins BCL-xL and MCL-1. The study provides a mechanistic rationale for sequential BH3-mimetic targeting while also defining important limits on how these findings should be translated beyond the tested glioblastoma models.

• Turning BCL-XL Dependence into Translational Leverage

  2026-10-01

  A mechanistic and strategic analysis of BCL-XL dependence, apoptosis priming, and how A-1155463 can support translational cancer research across solid-tumor and hematological models.

• Z-YVAD-FMK: A Translational Lens on Cell Death

  2026-10-01

  Z-YVAD-FMK provides a focused pharmacological way to interrogate caspase-1, inflammasome signaling, and pyroptotic cell death while helping translational researchers separate inflammatory caspase activity from ferroptosis and apoptosis. This article connects the inhibitor’s experimental value with recent AML ferroptosis findings and outlines a practical strategy for pathway-resolved study design.

• DNase I (RNase-free) for RNA Workflow Control

  2026-10-01

  Learn how to use ribonuclease-free DNase I to remove genomic DNA without compromising RNA-focused workflows. This guide connects practical DNA cleanup with RT-PCR, in vitro transcription, chromatin assays, and translational sensory-neuron research.

• ABT-263 Workflow for Mitochondrial Apoptosis

  2026-09-30

  Build more informative apoptosis assays with ABT-263 (Navitoclax), from controlled dose-response screens to mechanism-focused combination studies. This workflow connects Bcl-2-family inhibition with orthogonal death readouts and the emerging concept that Pol II degradation can activate cell death independently of transcriptional loss.

7986 records 1/533 page Next 12345 下5页 Last page